Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCan-Fite Biopharma Ltd Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$27.00 | -$27.00 | -$27.00 |
| Q2 2026 | 1 | -$31.00 | -$31.00 | -$31.00 |
| Q3 2026 | 1 | -$14.00 | -$14.00 | -$14.00 |
| Q4 2026 | 1 | -$34.00 | -$34.00 | -$34.00 |
| Q1 2027 | 1 | -$28.00 | -$28.00 | -$28.00 |
| Q2 2027 | 1 | -$14.67 | -$14.67 | -$14.67 |
| Q3 2027 | 1 | -$18.00 | -$18.00 | -$18.00 |
| Q4 2027 | 1 | -$18.26 | -$18.26 | -$18.26 |
| Q1 2028 | 1 | -$14.19 | -$14.19 | -$14.19 |
| Q2 2028 | 1 | -$12.32 | -$12.32 | -$12.32 |
| Q3 2028 | 1 | -$8.59 | -$8.59 | -$8.59 |
| Q4 2028 | 1 | -$5.29 | -$5.29 | -$5.29 |
| Q1 2029 | 1 | -$0.62 | -$0.62 | -$0.62 |
| Q2 2029 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q3 2029 | 1 | -$0.51 | -$0.51 | -$0.51 |
| Q4 2029 | 1 | -$0.53 | -$0.53 | -$0.53 |
| Q1 2030 | 1 | -$0.15 | -$0.15 | -$0.15 |
| Q2 2030 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2030 | 1 | -$0.00 | -$0.00 | -$0.00 |
Can-Fite Biopharma Ltd Earnings Date And Information
Can-Fite Biopharma Ltd last posted its earnings results on Thursday, March 26th, 2026. The company reported $-5.97 earnings per share for the quarter, topping analysts' consensus estimates of $-26.9973 by $21.0273. The company had revenue of 101.00 K for the quarter and had revenue of 408.21 K for the year. Can-Fite Biopharma Ltd has generated $-12 earnings per share over the last year ($-12.03 diluted earnings per share) and currently has a price-to-earnings ratio of -885.4. Can-Fite Biopharma Ltd has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Can-Fite Biopharma Ltd Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 06/30/2025 | Q2 2025 | N/A | -$0.21 | N/A | $500.00 K | $101.00 K |
| 03/31/2025 | Q1 2025 | N/A | -$0.21 | N/A | N/A | $101.00 K |
| 12/31/2024 | Q4 2024 | N/A | -$0.24 | N/A | N/A | $179.00 K |
| 09/30/2024 | Q3 2024 | N/A | -$0.24 | N/A | $150.00 K | $179.00 K |
| 06/30/2024 | Q2 2024 | N/A | -$0.33 | N/A | $300.00 K | $158.00 K |
| 03/31/2024 | Q1 2024 | N/A | -$0.33 | N/A | N/A | $158.00 K |
| 12/30/2023 | Q4 2023 | N/A | -$0.33 | N/A | N/A | $155.00 K |
| 09/29/2023 | Q3 2023 | N/A | -$0.42 | N/A | N/A | $196.00 K |
| 06/29/2023 | Q2 2023 | N/A | -$0.42 | N/A | N/A | $196.00 K |
| 03/30/2023 | Q1 2023 | N/A | -$0.66 | N/A | N/A | $196.00 K |
| 12/30/2022 | Q4 2022 | N/A | -$1.11 | N/A | N/A | $197.00 K |
| 09/30/2022 | Q3 2022 | N/A | -$0.93 | N/A | N/A | $204.00 K |
| 06/30/2022 | Q2 2022 | N/A | -$0.81 | N/A | N/A | $204.00 K |
| 03/31/2022 | Q1 2022 | N/A | -$0.90 | N/A | N/A | $205.00 K |
| 12/31/2021 | Q4 2021 | N/A | -$3.03 | N/A | N/A | $204.00 K |
| 09/30/2021 | Q3 2021 | N/A | -$1.86 | N/A | N/A | $251.00 K |
| 06/30/2021 | Q2 2021 | N/A | -$1.86 | N/A | N/A | $250.00 K |
| 03/31/2021 | Q1 2021 | N/A | -$1.17 | N/A | N/A | $148.00 K |
| 12/31/2020 | Q4 2020 | N/A | -$2.34 | N/A | N/A | $150.00 K |
| 09/30/2020 | Q3 2020 | N/A | -$1.68 | N/A | N/A | $211.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Can-Fite Biopharma Ltd Earnings: FAQ's
In the previous quarter, Can-Fite Biopharma Ltd (:CANF) reported $-5.97 earnings per share (EPS) to beat the analysts' consensus estimate of $-26.9973 by $21.0273.
The conference call for Can-Fite Biopharma Ltd's latest earnings report can be listened to online.
The conference call transcript for Can-Fite Biopharma Ltd's latest earnings report can be read online.
Can-Fite Biopharma Ltd (:CANF) has a recorded annual revenue of $408.21 K.
Can-Fite Biopharma Ltd (:CANF) has a recorded net income of $-9,905,965.Can-Fite Biopharma Ltd has generated $-12.03 earnings per share over the last four quarters.
Can-Fite Biopharma Ltd (:CANF) has a price-to-earnings ratio of -885.4 and price/earnings-to-growth ratio is -17.89.